- Home
- LYEL vs EBS Comparison
LYEL vs EBS Comparison
Compare LYEL & EBS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | LYEL | EBS |
|---|---|---|
| Founded | 2018 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 548.9M | 595.6M |
| IPO Year | 2021 | 2006 |
Fundamental Metrics
Financial Performance| Metric | LYEL | EBS |
|---|---|---|
| Price | $23.00 | $10.90 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 1 |
| Target Price | ★ $25.00 | $15.00 |
| AVG Volume (30 Days) | 89.8K | ★ 522.0K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 75.76 |
| EPS | N/A | ★ 1.89 |
| Revenue | $61,000.00 | ★ $1,043,600,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $15.21 |
| P/E Ratio | ★ N/A | $5.74 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.39 | $4.02 |
| 52 Week High | $45.00 | $14.06 |
Technical Indicators
Market Signals| Indicator | LYEL | EBS |
|---|---|---|
| Relative Strength Index (RSI) | 43.89 | 45.93 |
| Support Level | $21.72 | $10.50 |
| Resistance Level | $27.30 | $12.60 |
| Average True Range (ATR) | 2.60 | 0.53 |
| MACD | -0.09 | 0.02 |
| Stochastic Oscillator | 36.63 | 46.21 |
Price Performance
Historical ComparisonAbout LYEL Lyell Immunopharma Inc.
Lyell Immunopharma Inc is a clinical-stage cell therapy company. It has a pipeline of product candidates for patients with solid tumors utilizing ex vivo genetic and epigenetic T-cell reprogramming technologies. The company's product pipeline includes, LYL797, LYL119, LYL845 among others.
About EBS Emergent Biosolutions Inc.
Emergent BioSolutions Inc offers public health products to the government and healthcare providers. Company operates in three segments namely Commercial Product, MCM Products, and Services segment. The Commercial Product Segment consisting of Nasal Spray; the MCM Products Segment consisting of Anthrax-MCM products, Smallpox-MCM products and Other Products and the Services Segment consisting of Bioservices portfolio. The key revenue is generated through the commercial segment which consists of NARCAN and other commercial products.